Catrin Cox

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Robert H. Jones, Angela Casbard, Margherita Carucci et al. · The Lancet Oncology · 2020 · 220 citations · Full text

Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy

Roohi Ismail‐Khan, S. Minton, Catrin Cox et al. · Journal of Clinical Oncology · 2008 · 53 citations

Reproductive Sciences, Breast Oncology, Reproductive Health +23

Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma

Michelle R. Goulart, Jennifer Watt, Imran Siddiqui et al. · npj Precision Oncology · 2021 · 24 citations · Full text

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

Somnath Mukherjee, Ganesh Radhakrishna, Sarah Gwynne et al. · European Journal of Cancer · 2021 · 18 citations · Full text

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer

Frances Willenbrock, Catrin Cox, Eileen E. Parkes et al. · British Journal of Cancer · 2020 · 14 citations · Full text